药物临床试验登记与信息公示平台数据显示,Pfizer Inc./辉瑞投资有限公司/BSP Pharmaceuticals S.p.A的一项在既往接受过治疗的程序性细胞死亡配体1 (PD - L1) 阳性非小细胞肺癌(NSCLC) 成人研究参与者中评价PF - 08046054/SGN - PDL1V相比多西他赛的随机、III期、开放性研究已启动。临床试验登记号为CTR20253854,首次公示信息...
Source Link药物临床试验登记与信息公示平台数据显示,Pfizer Inc./辉瑞投资有限公司/BSP Pharmaceuticals S.p.A的一项在既往接受过治疗的程序性细胞死亡配体1 (PD - L1) 阳性非小细胞肺癌(NSCLC) 成人研究参与者中评价PF - 08046054/SGN - PDL1V相比多西他赛的随机、III期、开放性研究已启动。临床试验登记号为CTR20253854,首次公示信息...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.